Using machine learning to assess heart health in patients with transthyretin cardiac amyloidosis
Valeur Pronostique Dans Une Population d'Amylose Cardiaque Des paramètres échocardiographiques basée Sur Une Approche d'Apprentissage Automatique
This study is testing whether using machine learning on heart scans and blood tests can help doctors better understand and predict the health of patients with transthyretin cardiac amyloidosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 4 sites (Créteil and 3 other locations) |
| Trial ID | NCT05772091 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prognostic value of echocardiographic parameters in patients suspected of having transthyretin cardiac amyloidosis using a machine learning approach. The study will analyze non-invasive diagnostic methods, including imaging and biological markers, to better understand the disease's progression and associated risks. By leveraging machine learning techniques, the study seeks to enhance the predictive capabilities for patient outcomes in this currently incurable condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have a suspicion of transthyretin cardiac amyloidosis.
Not a fit: Patients who lack sufficient diagnostic data to confirm transthyretin amyloidosis or have been diagnosed with AL or AA amyloidosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and management strategies for patients with transthyretin cardiac amyloidosis.
How similar studies have performed: While machine learning has shown promise in diagnostic applications, the prognostic approach in this specific context is novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspicion of transthyretin cardiac amyloidosis * Age ≥18 years Exclusion Criteria: * Lack of data to confirm or overturn the transthyretin amyloidosis diagnostic * Echocardiographic data not allowing deep analysis (technical default, bad echogenicity of the patient) * Final diagnostic of AL or AA amyloidosis
Where this trial is running
Créteil and 3 other locations
- Hôpitaux Universitaires Henri Mondor — Créteil, France (Not_yet_recruiting)
- CHRU de Nancy — Nancy, France (Recruiting)
- CHU de Rennes Hôpital Pontchaillou — Rennes, France (Not_yet_recruiting)
- CHU de Toulouse — Toulouse, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Olivier HUTTIN, MD, PhD
- Email: o.huttin@chru-nancy.fr
- Phone: + 33 3 83 15 73 55
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.